Levofloxacin

Generic Name
Levofloxacin
Brand Names
Levaquin, Quinsair
Drug Type
Small Molecule
Chemical Formula
C18H20FN3O4
CAS Number
100986-85-4
Unique Ingredient Identifier
RIX4E89Y14
Background

Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication

In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions
Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)

First Posted Date
2018-10-05
Last Posted Date
2020-12-19
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
62
Registration Number
NCT03697993
Locations
🇺🇸

Brigham and Women's Hospital - Infectious Diseases, Boston, Massachusetts, United States

🇺🇸

Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

University of California Los Angeles - Olive View Medical Center, Sylmar, California, United States

and more 9 locations

Topical Antibiotics in Chronic Rhinosinusitis

First Posted Date
2018-09-17
Last Posted Date
2022-04-20
Lead Sponsor
Mayo Clinic
Target Recruit Count
19
Registration Number
NCT03673956
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection

First Posted Date
2018-09-05
Last Posted Date
2018-11-26
Lead Sponsor
China Academy of Chinese Medical Sciences
Target Recruit Count
252
Registration Number
NCT03658291

Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients

First Posted Date
2018-07-20
Last Posted Date
2018-07-24
Lead Sponsor
Centre Henri Becquerel
Target Recruit Count
150
Registration Number
NCT03594149
Locations
🇫🇷

CHU Amiens, Amiens, France

🇫🇷

Centre Henri Becquerel, Rouen, France

🇫🇷

CHU Caen, Caen, France

and more 1 locations

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

First Posted Date
2018-04-27
Last Posted Date
2024-12-17
Lead Sponsor
Duke University
Target Recruit Count
1600
Registration Number
NCT03511118
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Loma Linda University Health, Loma Linda, California, United States

and more 19 locations

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

First Posted Date
2018-03-22
Last Posted Date
2023-08-14
Lead Sponsor
University College, London
Target Recruit Count
675
Registration Number
NCT03474198
Locations
🇮🇩

Saiful Anwar Hospital, Malang, Indonesia

🇺🇬

Joint Clinical Research Centre, Mbarara, Uganda

🇺🇬

Infectious Diseases Institute, Kampala, Uganda

and more 14 locations

Tailored Therapy for Helicobacter Pylori Rescue Treatment

First Posted Date
2018-01-29
Last Posted Date
2018-08-07
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
200
Registration Number
NCT03413020
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy

First Posted Date
2017-06-06
Last Posted Date
2017-06-06
Lead Sponsor
Mansoura University
Target Recruit Count
300
Registration Number
NCT03178292
Locations
🇪🇬

Urology and Nephrology Center, Mansoura, Aldakahlia, Egypt

Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections

Phase 4
Conditions
Urinary Tract Infection
Interventions
Drug: Levofloxacin
First Posted Date
2017-05-19
Last Posted Date
2017-05-19
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
214
Registration Number
NCT03160807
Locations
🇰🇿

Scientific Centre of Urology named after B.U Dzharbusynov 2, Basenov street,, Almaty, Kazakhstan

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

First Posted Date
2017-05-03
Last Posted Date
2017-05-03
Lead Sponsor
Yanqing Li
Target Recruit Count
120
Registration Number
NCT03139253
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy